Management and Treatment of Contact Urticaria Syndrome

  • Gustavo Deza
  • Ana M. Giménez-ArnauEmail author
Part of the Updates in Clinical Dermatology book series (UCD)


Contact urticaria syndrome (CUS) is characterized by the development of itchy wheals and/or eczematous dermatitis that usually appears within minutes after the contact with an eliciting substance. Over the years, advances in the knowledge of the pathogenesis of this condition have caused changes in its classification, diagnosis, and treatment. Management of CUS is similar to that of other diseases caused by hypersensitivity reactions. Thus, the safest and most effective measure is the complete avoidance of the particular allergen. In cases where prevention has failed and symptoms interfere too greatly with the patient’s career and/or quality of life, pharmacological agents could be used to provide symptomatic relief. Nevertheless, this pharmacological therapy could vary depending on the type of immediate contact skin reaction and its pathophysiology. Herein, we discuss the different therapeutic options available for the management of CUS and review the mechanisms by which these agents might achieve their therapeutic effects on patients with CUS.


Allergen Antihistamines Contact urticaria Contact urticaria syndrome Immediate contact skin reactions Prevention Protein contact dermatitis Urticaria 


  1. 1.
    Wakelin SH. Contact urticaria. Clin Exp Dermatol. 2001;26(2):132–6.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gimenez-Arnau A, Maurer M, De La Cuadra J, Maibach H. Immediate contact skin reactions, an update of contact urticaria, contact urticaria syndrome and protein contact dermatitis – “A never ending story”. Eur J Dermatol. 2010;20(5):552–62.PubMedGoogle Scholar
  3. 3.
    Maibach HI, Johnson HL. Contact urticaria syndrome. Contact urticaria to diethyltoluamide (immediate-type hypersensitivity). Arch Dermatol. 1975;111(6):726–30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Aquino M, Mawhirt S, Fonacier L. Review of contact urticaria syndrome- evaluation to treatment. Curr Treat Options Allergy. 2015;2(4):365–80.CrossRefGoogle Scholar
  5. 5.
    Bhatia R, Alikhan A, Maibach HI. Contact urticaria: present scenario. Indian J Dermatol. 2009;54(3):264–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang CY, Maibach HI. Immunologic contact urticaria- the human touch. Cutan Ocul Toxicol. 2013;32(2):154–60.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Von Krogh G, Maibach HI. The contact urticaria syndrome- an updated review. J Am Acad Dermatol. 1981;5(3):328–42.CrossRefGoogle Scholar
  8. 8.
    McFadden J. Immunologic contact urticaria. Immunol Allergy Clin N Am. 2014;34(1):157–67.CrossRefGoogle Scholar
  9. 9.
    Verhulst L, Goossens A. Cosmetic components causing contact urticaria: a review and update. Contact Dermatitis. 2016;75(6):333–44.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Nicholson PJ, Llewellyn D, English JS, Guidelines Development Group. Evidence-based guidelines for the prevention, identification and management of occupational contact dermatitis and urticaria. Contact Dermatitis. 2010;63(4):177–86.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Adisesh A, Robinson E, Nicholson PJ, Sen D, Wilkinson M, Standards of Care Working Group. U.K. standards of care for occupational contact dermatitis and occupational contact urticaria. Br J Dermatol. 2013;168(6):1167–75.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chowdhury MMU. Occupational contact urticaria: a diagnosis not to be missed. Br J Dermatol. 2015;173(6):1364–5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Amaro C, Goossens A. Immunological occupational contact urticaria and contact dermatitis from proteins: a review. Contact Dermatitis. 2008;58(2):67–75.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dean AM, Secrest AM, Powell DL. Contact urticaria from occupational exposure to formaldehyde. Dermatitis. 2016;27(4):232.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Saluja SS, Davis CL, Chong TA, Powell DL. Contact urticaria to nickel: a series of 11 patients who were prick test positive and patch test negative to nickel sulfate 2.5% and 5.0%. Dermatitis. 2016;27(5):282–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gomułka K, Panaszek B. Contact urticaria syndrome caused by haptens. Postepy Dermatol Alergol. 2014;31(2):108–12.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Venarske D, deShazo RD. Molecular mechanisms of allergic disease. South Med J. 2003;96(11):1049–54.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lahti A, Oikarinen A, Viinikka L, Ylikorkala O, Hannuksela M. Prostaglandins in contact urticaria induced by benzoic acid. Acta Derm Venereol. 1983;63(5):425–7.PubMedGoogle Scholar
  19. 19.
    Lahti A, Väänänen A, Kokkonen EL, Hannuksela M. Acetylsalicylic acid inhibits non-immunologic contact urticaria. Contact Dermatitis. 1987;16(3):133–5.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Johansson J, Lahti A. Topical non-steroidal anti-inflammatory drugs inhibit non-immunologic immediate contact reactions. Contact Dermatitis. 1988;19(3):161–5.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Morrow JD, Minton TA, Awad JA, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans following the application of sorbic acid. Arch Dermatol. 1994;130(11):1408–12.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Levin C, Warshaw E. Protein contact dermatitis: allergens, pathogenesis, and management. Dermatitis. 2008;19(5):241–51.PubMedGoogle Scholar
  23. 23.
    Kanerva L, Estlander T. Immediate and delayed skin allergy from cow dander. Am J Contact Dermat. 1997;8(3):167–9.PubMedGoogle Scholar
  24. 24.
    Conde-Salazar L, González MA, Guimaraens D. Type I and Type IV sensitization to Anisakis simplex in 2 patients with hand eczema. Contact Dermatitis. 2002;46(6):361.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mercader P, de la Cuadra-Oyanguren J, Rodríguez-Serna M, Pitarch-Bort G, Fortea-Baixauli JM. Treatment of protein contact dermatitis with topical tacrolimus. Acta Derm Venereol. 2005;85(6):555–6.PubMedGoogle Scholar
  26. 26.
    Giménez-Arnau A. Contact urticaria and the environment. Rev Env Health. 2014;29(3):207–15.CrossRefGoogle Scholar
  27. 27.
    Alfonso JH, Bauer A, Bensefa-Colas L, Boman A, Bubas M, Constandt L, et al. Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206). J Eur Acad Dermatol Venereol. 2017;31(Suppl 4):31–43.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Mälkönen T, Jolanki R, Alanko K, Luukkonen R, Aalto-Korte K, Lauerma A, et al. A 6-month follow-up study of 1048 patients diagnosed with an occupational skin disease. Contact Dermatitis. 2009;61(5):261–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–87.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing and management of chronic inducible urticarias – The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780–802.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Deza G, Giménez-Arnau AM. Itch in urticaria management. Curr Probl Dermatol. 2016;50:77–85.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4):489–98.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Jáuregui I, Ferrer M, Montoro J, Dávila I, Bartra J, del Cuvillo A, et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007;17(2):41–52.PubMedGoogle Scholar
  34. 34.
    Khalaf AT, Li W, Jinquan T. Current advances in the management of urticaria. Arch Immunol Ther Exp. 2008;56(2):103–14.CrossRefGoogle Scholar
  35. 35.
    Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203–17.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Thurmond RL, Kazerouni K, Chaplan SR, Greenspan AJ. Antihistamines and itch. Handb Exp Pharmacol. 2015;226:257–90.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lee EE, Maibach HI. Treatment of urticaria. An evidence-based evaluation of antihistamines. Am J Clin Dermatol. 2001;2(1):27–32.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1–22.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kaplan AP. Treatment of chronic urticaria: approaches other than antihistamines. In: Kaplan A, Greaves M, editors. Urticaria and angioedema. New York: Informa Healthcare; 2009. p. 365–72.Google Scholar
  40. 40.
    Lebwohl MG, Del Rosso JQ, Abramovits W, Berman B, Cohen DE, Guttman E, et al. Pathways to managing atopic dermatitis: consensus from the experts. J Clin Aesthetic Dermatol. 2013;6(Suppl 7):S2–18.Google Scholar
  41. 41.
    Kozel MMA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs. 2004;64(22):2515–36.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed. 2008;24(1):19–23.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol. 1985;65(5):449–50.PubMedGoogle Scholar
  44. 44.
    Maxwell DL, Atkinson BA, Spur BW, Lessof MH, Lee TH. Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. J Allergy Clin Immunol. 1990;86(5):759–65.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res. 2005;297(3):134–8.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45(1):47–62.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Marsland AM, Soundararajan S, Joseph K, Kaplan AP. Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clin Exp Allergy. 2005;35(5):554–9.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C. Structural and physical basis for anti-IgE therapy. Sci Rep. 2015;5:11581.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. Drugs. 2014;74(14):1693–9.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Aubin F, Avenel-Audran M, Jeanmougin M, Adamski H, Peyron JL, Marguery MC, et al. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study. J Am Acad Dermatol. 2016;74(3):574–5.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Metz M, Schütz A, Weller K, Gorczyza M, Zimmer S, Staubach P, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140:864. Scholar
  52. 52.
    Maurer M, Schütz A, Weller K, Schoepke N, Peveling-Oberhag A, Staubach P, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140:870. Scholar
  53. 53.
    Cirla AM. Asthma and baker’s allergy: experience with health programs. G Ital Med Lav Ergon. 2011;33(1):20–5.PubMedGoogle Scholar
  54. 54.
    Nettis E, Di Leo E, Calogiuri G, Milani M, Delle Donne P, Ferrannini A, et al. The safety of a novel sublingual rush induction phase for latex desensitization. Curr Med Res Opin. 2010;26(8):1855–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Hospital del Mar - Institut Mar d’Investigacions MediquesUniversitat Autònoma de Barcelona (UAB), Department of DermatologyBarcelonaSpain

Personalised recommendations